OS Therapies Gains Regulatory Clarity for OST-HER2 in Osteosarcoma, Stonegate Capital Reports
Stonegate Capital Partners updates coverage on OS Therapies, highlighting EMA rolling review and TGA endpoint alignment that shift OST-HER2 toward a global approval pathway, with key survival data catalysts in 2026.
Stonegate Capital Partners has updated its coverage on OS Therapies Inc. (NYSE: OSTX), emphasizing significant regulatory progress for its lead candidate OST-HER2 in recurrent, fully resected, pulmonary metastatic osteosarcoma. The European Medicines Agency (EMA) initiated a rolling review of the Conditional Marketing Authorization (CMA) dossier, while the EMA and Australia's Therapeutic Goods Administration (TGA) aligned on 3-year overall survival as the approvable efficacy endpoint. These developments provide greater regulatory clarity, moving OST-HER2 from Phase 2b-supported planning toward a defined global approval pathway.
The key implication for investors is that OST-HER2 is shifting from early proof-of-concept to execution, with a dense catalyst calendar in 2026. Management has positioned seroconversion biomarker data as supportive surrogate efficacy evidence, further strengthening the case for accelerated access. Upcoming milestones include 2.5-year overall survival (OS) data in mid-second quarter 2026, FDA and MHRA meetings in the second quarter, Phase 3 initiation in Australia in the third quarter, 3-year OS data in early fourth quarter, and a potential EMA CMA decision in the fourth quarter of 2026.
Regulatory clarity is the core value inflection point. The EMA rolling review and TGA endpoint alignment, combined with MHRA Advanced Therapy Medicinal Product (ATMP) designation and planned FDA and MHRA meetings in 2026, create an executable global pathway. Survival data remain the key catalyst stack, with mid-2026 2.5-year OS data and early-fourth quarter 2026 3-year OS data expected to determine whether OS Therapies can complete the EMA CMA submission and sustain accelerated-access momentum.
Financing and a potential Priority Review Voucher (PRV) provide optionality to bridge the regulatory window. The company raised $5.25 million, and an expected $4.0 million in non-dilutive funding supports 2026 catalysts. A potential PRV remains a meaningful approval-contingent valuation lever, with the latest public transaction at $205 million. For more details, view the full announcement here.
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services. Its affiliate, Stonegate Capital Markets (member FINRA), offers investment banking services. The updated coverage reflects the firm's ongoing analysis of OS Therapies' regulatory and clinical progress.